Collin M. Blakely

Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation.

Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.

A New Pathway Emerges to Interpret Lung Cancer Genomic Alterations.

Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.